N/A
Completed N=60
Lidocaine Combined Dexmedetomidine for Obturator Nerve Block
Nerve Block
Source: ClinicalTrials.gov NCT02066727 ↗
Enrolled (actual)
60
Serious AEs
0.0%
Results posted
Dec 2014
Primary outcomePrimary: Median Effective Concentration(EC50) — 5.7; 2.9 mg/ml(the concentration of lidocaine)
Summary
Hypothesis: Dexmedetomidine as an adjuvant of lidocaine can decrease the median effective concentration(EC50) of lidocaine for obturator nerve block during transurethral resection of bladder tumor
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Median Effective Concentration(EC50) |
5.7; 2.9 | — |
| SECONDARY Complication Related With Nerve Block |
— | — |
Eligibility Criteria
Inclusion Criteria
- Subjects scheduled to undergo elective operation of TURBT on lateral wall for whom ONB was needed diagnosed through cystoscopy or CT examination preoperatively.
- Subject's American Society of Anesthesiologists physical status is I-II.
- The subject's parent/legally authorized guardian has given written informed consent to participate.
Exclusion Criteria
- Subject has a diagnosis of abnormal coagulation function.
- Subject has a diagnosis of Diabetes mellitus.
- Subject has a preexisting neurologic deficits of the lower extremities.
- Subject has a history of alcohol or drug abuse.
- Subject is pregnant or breast-feeding.
- Subject is obese (body mass index >30kg/m2).
Data sourced from ClinicalTrials.gov (NCT02066727). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.